Trial · NCT00640510
Results by group20
Each measurement the trial posted, group by group, in the words and numbers it posted.
1 to 20 of 20
Download this page as JSON| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Change From Baseline to 2 Hours Post the First Intramuscular (IM) Injection in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) | IM Olanzapine 10mg | -4.7 | Standard Deviation 4.8 | units on a scale | |
| Change From Baseline to 2 Hours Post the First Intramuscular (IM) Injection in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) | IM Placebo | -4.6 | Standard Deviation 4.5 | units on a scale | |
| Change From Baseline to Each Timepoint in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) | IM Olanzapine 10mg | Change from Baseline to 15 minutes | -1.2 | Standard Deviation 1.3 | units on a scale |
| Change From Baseline to Each Timepoint in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) | IM Placebo | Change from Baseline to 15 minutes | -1.2 | Standard Deviation 1.5 | units on a scale |
| Change From Baseline to Each Timepoint in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) | IM Olanzapine 10mg | Change from Baseline to 30 minutes | -2.9 | Standard Deviation 2.8 | units on a scale |
| Change From Baseline to Each Timepoint in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) | IM Placebo | Change from Baseline to 30 minutes | -2.4 | Standard Deviation 2.8 | units on a scale |
| Change From Baseline to Each Timepoint in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) | IM Olanzapine 10mg | Change from Baseline to 60 minutes | -3.8 | Standard Deviation 3.6 | units on a scale |
| Change From Baseline to Each Timepoint in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) | IM Placebo | Change from Baseline to 60 minutes | -3.4 | Standard Deviation 4.1 | units on a scale |
| Change From Baseline to Each Timepoint in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) | IM Olanzapine 10mg | Change from Baseline to 90 minutes | -5.1 | Standard Deviation 4.3 | units on a scale |
| Change From Baseline to Each Timepoint in Positive and Negative Syndrome Scale-Excited Component (PANSS-EC) | IM Placebo | Change from Baseline to 90 minutes | -4.6 | Standard Deviation 4.7 | units on a scale |
| Number of Responders at 2 Hours After First Intramuscular (IM) Injection | IM Olanzapine 10mg | 3 | participants | ||
| Number of Responders at 2 Hours After First Intramuscular (IM) Injection | IM Placebo | 4 | participants | ||
| Number of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) at Each Timepoint | IM Olanzapine 10mg | 30 Minutes | 1 | participants | |
| Number of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) at Each Timepoint | IM Placebo | 30 Minutes | 1 | participants | |
| Number of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) at Each Timepoint | IM Olanzapine 10mg | 60 Minutes | 1 | participants | |
| Number of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) at Each Timepoint | IM Placebo | 60 Minutes | 1 | participants | |
| Number of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) at Each Timepoint | IM Olanzapine 10mg | 90 Minutes | 2 | participants | |
| Number of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) at Each Timepoint | IM Placebo | 90 Minutes | 2 | participants | |
| Number of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) at Each Timepoint | IM Olanzapine 10mg | 2 Hours | 3 | participants | |
| Number of Participants With Scores of 4 to 7 in the Agitation-Calmness Evaluation Scale (ACES) at Each Timepoint | IM Placebo | 2 Hours | 2 | participants |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT00640510/results